AUTHOR INDEX

Volume 29, 1994

Abe, M., 239, 579, 583, 587, 591, 595, 1089
Abra, R. M., 827
Abramson, D. H., 729
Adamietz, I. A., 183, 220
Adams, G. E., 231, 285, 329, 333, 339, 369, 443, 463
Adcock, L. L., 989
Agrawal, K. C., 397
Akaboshi, M., 81, 239
Akagi, K., 505
Akanuma, A., 631
Akashi, M., 631
Akuta, K., 81, 239
Alastuey, I., 1201
Alecci, M., 421
Aletti, P., 673, 681
Alexander, III, E., 617
Anderson, W. J., 781
Ando, K., 239, 621
Ang, K. K., 67
Antich, P. P., 95
Aoki, Y., 631
Aoyama, T., 627
Au, G. K. H., 699

Babcock, E. E., 95
Bacher, J. D., 1015
Baeker, J. R., 1085
Baguley, B. C., 373
Bahary, J.-P., 647
Baille-Johnson, H., 3
Bamberg, M., 869
Bardelli, D., 45
Barnes, M., 781
Bartelink, H., 205
Bauman, G. S., 835
Beard, C., 611
Belfi, C. A., 473
Bentel, G. C., 879, 903
Bentzen, S. M., 941
Berger, C., 17
Bergeron, R. J., 1041
Berkowitz, R., 545
Bernier, J., 1189
Berns, C., 855
Bertoni, F., 45
Bertrand, K., 1139
Bey, P., 673, 681
Bhattathiri, V. N., 383
Biaglow, J. E., 357
Bielajew, A. F., 1157
Bieri, S., 1167
Biti, G., 25
Blach, L. E., 735
Black, P. McL., 617
Black, P., 847
Boddi, V., 25
Boles, M., 1085
Bollinger, B. K., 781
Bonner, J. A., 243
Bosset, J.-F., 205
Böttcher, H. D., 183, 220
Botteron, P., 1167
Boulad, F., 847
Bouzy, J., 953
Bowen, M. G., 529
Boyce, D. J., 459
Bradley, J. K., 329, 463
Brady, L. W., 1049
Brambs, H.-J., 855
Brand, R., 711
Braunhut, S. J., 249
Bremner, J. C. M., 285, 329, 463
Brenner, D. J., 893
Britsch, A., 687
Brochstein, J., 847
Brown, A. E., 163
Brown, I., 115
Brown, J. M., 493
Broxmeyer, H. E., 821
Bump, E. A., 249, 407, 289
Burman, C. M., 755
Busse, P. M., 535
Buswell, L., 535, 541, 545, 611
Butler, E. B., 213
Byhardt, R. W., 661

Cahill, R., 39
Cairncross, J. G., 835
Capellari, J. O., 841
Caplan, R. J., 1183
Carlson, J. W., 989
Carmichael, J., 277, 369
Carson, L. F., 989, 1079
Castro, J. R., 647, 1027
Castro-Malaspina, H., 847
Catton, C. N., 1005
Cavaletti, G., 763
Cellai, E., 25
Cerce, B. A., 249
Chadwick, J. A., 499
Chan, W., 813
Chandini, R., 383
Chaplin, D. J., 363, 439, 467, 499
Chapman, J. D., 351
Chappell, R., 191
Chen, C.-Z., 1041
Chen, E. Y., 259
Cheng, A. C. K., 699
Childs, B., 847
Choi, I.-B., 433
Choy, D., 699
Christensen, K. L., 455
Christianson, T. J. H., 243
Chung, C. T., 177, 1085
Ciottoli, G. B., 45
Clark, J., 535
Clery, M., 661, 961
Cliffe, S., 323
Cole, S., 339
Coleman, C. N., 249, 289, 357, 379, 407, 535, 541, 545, 611, 617
Collier, J. M., 647
Constantinescu, A., 95
Cook, J. A., 559
Cooper, J. S., 661
Corn, B., 969
Coughlin, C. T., 1065
Counsell, C. J. R., 285
Cox, J. A., 1119
Cox, J. D., 1183
Cruikshank, G., 427
Cummings, B. J., 195, 1005
Cygler, J., 1157

Daftari, I., 647
Dartois, D., 681
Dass, K. K., 187
Davis, M. A., 519
Deeg, H. J., 39
Deen, D. F., 1041
DeLaney, T. F., 735
Delfs, J. R., 289
DeLuca, A. M., 781, 1015
Denison, L., 549
Denny, W. A., 311, 317, 323
DePriest, P., 529
Ding, L., 393
Doggett, R. L. S., 661, 961
Doherty, N., 379
Donaldson, S. S., 883
Dorie, M. J., 805
Down, J. D., 218
Durand, R. E., 481, 487
Dusenbery, K. E., 989, 1079

Edgren, M. R., 403
Edmonds, P. M., 3
Edwards, D. I., 307
Efird, J. T., 657
Eifel, P. J., 9
Eisbruch, A., 217
Elkind, M. M., 577
Ellsworth, R. M., 729
Emami, B., 1105
Engin, K., 125
Ennis, R., 1133
Erickson, B. A., 1095
Eschwege, F., 149
Evans, G., 999

Fariss, A. K., 177
Feeley, M. M., 133
Fein, D. A., 169
Fenton, B. M., 459
Ferrari, M., 421
Fielden, E. M., 333, 339
Fietkau, R., 1049
Fisher, B. J., 835
Fisher, J., 559
Fitzpatrick, P. J., 195
Fitzsimmons, S. A., 427
Flomenberg, N., 847
Folven, B. R., 243
Fontanesi, J., 1199
Fornasier, V., 1005
Fowler, J. F., 105, 209, 989, 1079, 1195
Fraas, B. A., 1125
Frazier, L. C., 841
Freeman, D. E., 169, 983
Freund, U., 855
Fries, P. D., 177
Fritz, P., 855
Fu, K. K., 661
Fuchihata, H., 705
Fuks, Z., 755, 847, 863
Furukawa, S., 705

Gabel, M., 555
Gadner, H., 39
Gallion, H. H., 529
Gaspar, L. E., 835
Gauger, G., 647
Geard, C. R., 267, 565
Geisinger, K. R., 841
George, W. J., 397
Gerard, J.-P., 17, 215
Gerbaulet, A., 953
Gerritsen, M., 295
Gerweck, L. E., 57
Giaccia, A. J., 259
Gillio, A., 847
Glasgow, G. P., 1175
Glazer, H. S., 1105
Gogu, S. R., 397
Goodman, H., 545
Gospodarowicz, M. K., 195
Goswitz, J. J., 989
Gould, R. C., 216
Graham, M. V., 1105
Grant, W., 213
Grau, C., 439, 449
Green, A., 549
Green, M. R., 1085
Greven, K. M., 841
Griffin, R. J., 433
Griffin, T. W., 1187
Griffith, O. W., 407
Grigsby, P. W., 217, 961
Grob, E., 1167
Gutin, P. H., 647, 719

Ha-Kawa, S. K., 505
Haaxma-Reiche, H., 711
Habara, Y., 511
Hahn, E. W., 95
Hahn, G. M., 827
Haie-Meder, C., 953

Hall, E. J., 267, 273, 891, 893
Hallahan, D. E., 777
Halperin, E. C., 835
Hamers, H. P., 205
Hammond, E., 661
Hampshire, V. A., 1015
Hancock, S. L., 379
Hanson, W. R., 273
Hao, Y., 1005
Happersett, L., 755
Haraf, D. J., 153, 216
Harari, P. M., 209
Harkness, B. A., 841
Harms, Sr., W. B., 1105
Harris, A. L., 277, 369
Harris, G. J., 1095
Harrison, A., 755
Harrison, L., 863
Harter, K. W., 1139
Hasegawa, T., 433, 505
Hayakawa, K., 975
Hazard, L., 357
Healy, J. B., 925
Hebert, M. E., 903
Hei, T. K., 267
Heimans, J. J., 1201
Hermans, J., 711
Herndon, J. E., 1085
Hess, C. F., 869
Hilburger, C. L., 397
Hill, R. P., 373
Hill, S. A., 439, 499
Hirschfeld, F., 1147
Hoekstra, F. H., 711
Hoffstetter, S., 673, 681
Hogan, W. M., 969
Holmes, M. A., 1157
Holt, P. J., 1079
Hoopes, P. J., 1065
Hope-Stone, H. F., 3
Hori, H., 601
Horiot, J.-C., 205
Hornback, N. B., 821
Horowitz, M. E., 735
Horsman, M. R., 439, 449, 455, 499
Hoskin, P. J., 1011
Houlbrook, S., 369
Hricak, H., 201
Hu, L. J., 1041
Hua, B. Y., 607
Huan, L. C., 607
Huang, A. H., 827
Huang, Y., 893
Hurwitz, S. J., 289, 407, 545
Hussey, D. H., 1191

Ikebuchi, M., 627
Ikeda, H., 705
Inayama, S., 601
Inoue, T., 705
Iro, H., 1049
Ishigaki, T., 587
Isono, K., 621
Iwai, H., 579, 591, 595

Jackson, A. W., 3
Jacobson, J., 735
Jaiswal, A. K., 351
Jany, R., 869
Jin, Y., 393
Johnson, D., 611
Johnstone, P. A. S., 735, 781, 1015
Jones, J. M., 565
Joseph, P., 351

Kagan, A. R., 197
Kaklamanis, L., 277
Kalish, L. A., 541, 545
Kallman, R. F., 805
Kalra, R., 285
Kanno, T., 511
Kano, E., 511
Karim, A. B. M. F., 33, 1201
Kawase, Y., 631
Kaye, S., 379
Kelly, D. P., 549
Kernan, N., 847
Kessler, M. L., 1125
Keyes, Jr., J. W., 841
Khalil, A. A., 439, 449
Khil, M. S., 555
Kikuchi, H., 1089
Kim, C. Y., 259
Kim, I. H., 493
Kim, J. H., 555
Kim, S. H., 555
Kimura, H., 627
King, G. A., 177
Kinsella, T. J., 105, 781, 1015, 1195
Kitakabu, Y., 583
Koch, C. J., 345, 357
Koike, S., 239, 621
Kollath, J., 183
Kondo, T., 511
Koong, A. C., 259
Koper, P. C. M., 873
Kortmann, R.-D., 869
Kotwall, C., 1005
Kozin, S. V., 505
Kozminski, P., 673, 681
Kramar, A., 953
Kreth, F. W., 220
Kubo, K., 705
Kufe, D. W., 777
Kusumoto, T., 545
Kutcher, G. J., 755
Kwok, T. T., 255
Kwong, D. L. W., 699
Kwong, P. W. K., 699

Lai, L. L., 249, 407
Lambin, P., 953
Lambooij, N., 711
LaNasa, P., 273
Lancar, R., 953
Lanciano, R., 969
Langley, R. E., 249, 289
LaPorte, R. M., 989
Larson, D. A., 719
Lartigau, E., 149
Laver, J., 847
Lawrence, T. S., 519
Lee, P. C., 1175
Lee, W. R., 983
Leeper, D. B., 125
Leibel, S. A., 755
Leigh, B. R., 221
LePard, N. E., 481
Levendag, P. C., 873
Lewis, A. D., 427
Liebman, J., 559
Liermann, D., 183
Lindeboom, J., 1201
Linstadt, D. E., 647
Loeffler, J. S., 617
Lonergan, S. J., 499
Lu, L., 821
Luboinski, B., 149
Luporsi, E., 673, 681
Lusinchi, A., 149
Lynch, E. M., 439

Macdonald, D. R., 835
Mack, T., 1147
Mackie, T. R., 1157
Macleod, K., 827
MacPhail, S., 87
Madewell, B. R., 1027
Magno, L., 45
Magrini, S. M., 25
Mahe, M. A., 17
Maihle, N. J., 243
Majno, S. B., 1167
Makepeace, C. M., 433
Malaker, K., 289, 407
Malec, M. K., 719
Malissard, L., 673, 681
Maltby, K., 789
Maniion, G., 205
Marcus, Jr., R. B., 169, 983
Mariscal, C., 379
Mark, L. P., 1095
Marks, L. B., 879, 903
Marquez, C., 379
Martin, E., 969
Martin, R. F., 549
Marton, L. J., 1041
Martus, P., 1049
Maruyama, Y., 529
Masaki, N., 705
Mason, R. P., 95
Massaro, B. M., 1095
Masunaga, S., 81, 239
Matsuno, E., 591
Matthews, D., 781
Matthews, J. W., 1105
Mauch, P. M., 218
Maybaum, J., 519
McCormick, B., 163, 729
McCunniff, A. J., 999
McDonald, S., 661, 747
McFarlane, J. D., 125
McGuire, W. A., 1079
McGuirt, W. F., 841
McMillan, T. J., 1035
Mcshan, D. L., 1125
McWilliams, D., 813
Medeiros, D., 249
Meisner, C., 869
Mendenhall, W. M., 169, 983
Menke, M., 1147
Metsaars, J. A. L., 711
Meyerowitz, C., 747
Mick, R., 153, 216
Miller, R. C., 273
Million, R. R., 169, 983
Milroy, R., 295
Minoia, C., 771
Miralbell, R., 1167
Mitchell, J. B., 357, 559
Mitchell, J. S., 115
Mithal, N. P., 1011
Mitsuhashi, N., 975
Montagut, J., 1201
Montero, M., 1167
Morgan, L. S., 169, 983
Mori, T., 601
Morris, M., 9
Moselen, J. W., 323
Moss, W. T., 687
Mott, T., 3
Muehlenkamp, J. K., 1157
Murakami, S., 705
Murata, R., 583, 587, 595
Murayama, C., 601
Muto, M., 545
Myskowski, P. L., 163

Nagasawa, H., 601
Nah, B. S., 433
Nair, M. K., 383
Nakajima, T., 601
Nakano, H., 525
Nakatani, K., 525
Nakatsugawa, S., 635
Naylor, M. A., 329, 339, 333
Needham, P. R., 1011
Ngo, F. Q. H., 473
Ni, C., 393
Niël, C. G. J. H., 873
Niibe, H., 975
Ning, S., 827
Niroomand-Rad, A., 1139
Nishimoto, S.-I., 579
Nishimura, Y., 141
Njo, K. H., 33
Nolan, J., 333
Noll, L., 611
Noordijk, E. M., 711
Nordsmark, M., 449
Nose, M., 631
Nouet, P., 1167
Nozaki, M., 975
Nyaruba, M. M., 627

O'Neill, P., 333
O'Reilly, R., 847
O'Sullivan, B., 1005
Oda, Y., 1089
Ohnishi, T., 525
Olive, P. L., 487
Oliver, R. T. D., 3, 215
Ong, J. Y. H., 3
Ono, K., 81, 239
Onoyama, Y., 601
Ortlieb, M., 39
Osborn, J. L., 433
Ostertag, Ch. B., 220
Ostrowski, M. J., 3
Oswald, M. J., 9
Overgaard, J., 439, 449, 455, 941
Oya, N., 579, 583, 587, 595

Padberg, G. W., 711
Paggiarino, D. A., 999
Pajak, T. F., 661, 1183

Palayoor, S. T., 249, 289
Papanikolaou, N., 1157
Papi, M. G., 25
Pardee, M., 549
Parkins, C. S., 499
Pastyr, O., 1147
Patterson, A. V., 369
Paul, C. R., 473
Pavy, J.-J., 205
Pedersen, D., 941
Peiffert, D., 673, 681
Pelissier, E. P., 205
Penney, D. P., 789
Percarpio, B., 1133
Perez, C. A., 217, 961
Pernot, M., 673, 681
Peschel, R. E., 1133
Peschke, P., 95
Petereit, D. G., 1195
Peters, C., 39
Peters, L. J., 67, 1189
Petti, P. L., 647
Philip, P. A., 277
Phillips, T. L., 201, 647, 719
Piao, C. Q., 267
Plumb, J. A., 295
Podgorsak, M. B., 1157
Ponticelli, P., 25
Porter, A. T., 1199
Potish, R. A., 989, 1079
Poulter, C. A., 961
Powell, S. N., 1035
Prados, M. D., 719
Pratt, W. R., 3
Precoma, J. C., 1167
Price, R. E., 67
Prosnitz, L. R., 903
Pullen, S. M., 317
Purdy, J. A., 1105

Quaresima, V., 421

Raaphorst, G. P., 133
Raben, M., 841, 1119
Rampling, R., 379, 427
Ravikumar, T., 535
Recht, A., 535
Reckwerdt, P. J., 1157
Reeves, N. J., 339, 463
Remani, P., 383
Rescigno, J., 163
Reum, M., 549
Révész, L., 403
Richardson, M. E., 387
Rider, B. J., 397
Riese, N. E., 407, 617
Ritter, M. A., 105
Roback, D. M., 989
Roberts, D. W., 1065
Roberts, M., 549
Robertson, N., 369
Rocher, F. P., 17
Rodriguez, R., 105
Roemeling, R. V., 379
Rogers, D. W. O., 1157
Romestaing, P., 17
Rose, M., 549
Rose, M. A., 611
Rosenblum, N., 969
Rosignoli, M. T., 45
Rouzaud, M., 1167
Roy, J., 863
Rubin, P., 1, 645, 747, 789, 933
Ruifrok, A. C. C., 73
Rutland, M., 373
Ryan, T. P., 1065
Ryley, N., 277
Ryu, J., 1027
Ryu, S., 555

Sachs, R. K., 893
Sagerman, R. H., 177
Sakurai, H., 975
Sampson, L. E., 467
Sanders, M., 213
Sansom, J. M., 285, 329, 443, 463
Saroff, D. M., 289
Sasai, K., 579, 583, 587, 591
Sauer, R., 1049
Sawada, H., 525
Sawicka, J. M., 1175
Scalliet, P., 953
Scarantino, C. W., 999
Scharfen, C. O., 719
Schell, M. C., 187
Scheremet, R., 220
Schieppati, M., 771
Schlegel, W., 1147
Schmidt, D. G., 1157
Schmidt-Ullrich, R. K., 813
Schopohl, B., 183
Schraube, P., 855
Schultheiss, T. E., 67, 969
Scott, C. S., 220
Seagren, S. L., 1085
Sebastian, P., 383
Seegenschmiedt, M. H., 1049
Senan, S., 379
Sham, J., 699
Shan, S., 473
Shank, B., 847
Shen, R.-N., 821
Sherouse, G. W., 903
Shibamoto, Y., 579, 583, 587, 591, 595, 1089
Shibata, T., 579, 583, 587, 595
Shidnia, H., 821
Shimizutani, K., 705
Shimm, D. S., 221
Shulman, L. N., 379, 541, 545
Siemann, D. W., 229, 301, 387, 419, 439, 789
Siim, B. G., 311
Simpson, J. R., 220
Sindelar, W. F., 781, 1015
Sipkema, D., 873
Skarsgard, L. D., 363
Skov, K. A., 87, 345
Skwarchuk, M. W., 369
Slotman, B. J., 33
Smudzin, T., 747
Sneed, P. K., 719
Snoek, F. J., 1201
Sohn, J. W., 187
Sombeck, M. D., 169, 983
Song, C. W., 433
Sotgiu, A., 421
Spain, K., 243
Spanos, Jr., W. J., 961
Spencer, D. P., 903
Spitzer, T. R., 39
Sprague, M., 1015
Sreelekha, T. T., 383
Steckel, R. J., 197
Steinfeld, A. D., 961
Stephens, L. C., 67, 73
Stephens, M. A., 369
Stevens, Jr., K. R., 687
Stobbe, C. C., 351
Storb, R., 218
Stratford, I. J., 231, 277, 285, 329, 333, 339, 369, 443, 463
Streffer, C., 571
Strohbehn, J. W., 1065
Sturm, V., 1147
Sugahara, T., 229, 419, 627, 635
Sugamoto, K., 627
Sugiyama, T., 595
Suh, J. H., 187
Sutcliffe, S. B., 195
Sutherland, R. M., 255
Sutton, B. M., 333, 339, 463
Suzuki, G., 631
Szabo, C., 443

Tada, T., 601
Takahashi, M., 579, 583, 975, 1089
Takahashi, T., 975
Tamulevicius, P., 571
Tanaka, Y., 505
Tans, J. Th. J., 711
Taphoorn, M. J. B., 1201
Taylor, M. L., 373
Teague, D., 559
Tefft, M. C., 39, 187
Teicher, B., 545
Ten Haken, R. K., 1125
Tepper, J. E., 781
Tercel, M., 317
Terraneo, F., 45
Terrill, R. E., 781, 1015
Théon, A. P., 1027
Thiemermann, C., 443
Thistlethwaite, A. J., 125
Thobejane, S., 1139
Thomas, A., 307
Thomson, P., 295
Tocher, J. H., 307
Tordiglione, M., 45
Torrisi, J., 39
Trask, C. W. L., 3
Tredici, G., 771
Trembly, B. S., 1065
Trillet-Lenoir, V., 17
Tupchong, L., 125
Tuttle, S. W., 357
Twiggs, L. B., 1079

Under, J. A., 989
Urano, M., 141
Urban, C., 39
Ursini, C. L., 421
Utsumi, H., 577

Valerie, K. C., 813
van der Kogel, A. J., 73
Van Nagell, J. R., 529
Van Zijl, P., 317
Vane, J. R., 443
Vecht, C. J., 711
Venzon, D. J., 735
Vijayakumar, T., 383
Vikse, C. M., 487
Vinczan, A., 363
Virudachalam, S., 777
Visser, A. G., 873
Vokes, E. E., 153, 216
Voormolen, J. H. C., 711

Wagner, J.-P., 17
Wainson, A. A., 403
Wallner, K., 863
Wan, K. Y., 699
Wang, C. C., 657
Wang, W., 393
Wannenmacher, M., 855
Wara, W. M., 719
Ware, D. C., 323
Warnke, P. C., 220
Wasserman, T. H., 229, 419
Watanabe, A., 525
Watson, Jr., N. E., 841
Wattendorff, A. R., 711
Weaver, K. A., 719
Weichselbaum, R. R., 153, 216, 777
Wells, C. M. M., 1157
Wen, P., 617
Wexler, L. H., 735
Wharton, J. T., 9
White, L. E., 397
Wierzbicki, J., 529
Wilkinson, J. M., 217
Williams, III, D. W., 841
Williams, M. V., 3
Williamson, J. F., 217
Wilson, J. F., 935
Wilson, L. D., 1133
Wilson, W. R., 311, 317, 323, 373
Wiltshire, C. R., 3
Wolf, R., 277
Wong, W. W., 153, 216
Woo, S. Y., 213
Wood, P. J., 285, 443, 463
Workman, P., 295, 427

Yaes, R. J., 924
Yamada, S., 621
Yamada, Y., 525
Yamakawa, M., 975
Yamashita, J., 1089
Yang, J. C., 735
Yano, T., 525
Yau, C. C., 699
Yi, X., 393
Yoshizawa, T., 579
Young, C. W., 999
Young, J., 847
Young, P., 821
Yuo, H. S., 177

Zaghloul, M. S., 805
Zagoria, R. J., 1119
Zaidi, S. T., 57
Zelefsky, M. J., 755
Zelefsky, M., 863
Zietman, A., 57

SUBJECT INDEX

Volume 29, 1994

A

Accelerated
  Fractionation, 149, 617
  Radiotherapy, 711
Accuracy, 1175
Acute toxicity, 595
Adjuvant, 3
Adrenochrome monoaminoguanidine methanesulfonate, 635
Age, 73
AK-2123, 607
Alkaline phosphatase, 115
Alternating chemo-radiotherapy, 1085
Anal canal carcinoma, 17
Anemia, 1079
Animal models, 1015
Aorta, 781
Aplastic anemia, 847
Apoptosis, 249, 289
Astatine-211, 115
Asymmetric collimator, 187
Azo/azoxy derivatives, 307

B

BE-4-4-4, 1041
Benzyl quarternary mustard, 317
Bile duct(s), 781, 855
Bioreduction, 307
Bioreductive
  Agents, 295
  Drug(s), 231, 311, 333, 317, 373
  Enzymes, 427
  Metabolism, 339, 357
  Therapy, 427
Bleomycin, 705
Blood
  Flow, 481, 505
  Pressure, 455
Bone marrow, 81
  Transplant, 1167
  Transplantation, 847
Bone metastases, 1011
Brachytherapy, 17, 617, 673, 681, 855, 863, 873, 893, 1049
Brain, 571
Brain, 1065
  Neoplasm, 719, 1089
  Tumors, 617
Breast
  Cancer, 163
  Positioning device, 879
  Conserving therapy, 163
Breast carcinoma, 879
  Cells, 813
Buthionine sulfoximine, 403, 407, 3983
BW 589C, 285

C

Calcium, 511
Canine, 1015
Carbogen, 81
Carbon monoxide breathing, 449
Carboplatin, 3, 545
Carboxyhemoglobin, 449
Carcinoma, 863
  Uterine cervix, 941
Cardiac toxicity, 903
Carotid cannulation, 455
CCNU, 301
CDDP, 525
CDF1 mice, 455
Cell
  Cycle, 267
  Kinetics, 105
  Membrane, 383
  Survival, 273
Cellulitis, 163
Central nervous system, 67
Cepharanthin, 525
Cerebrospinal fluid cytology, 1089
Cervical
  Cancer, 9, 873, 975
  Carcinoma, 953
Cervix cancer, 969, 1079
^{252}Cf, 529
CFU-GM, 631
Charged particle radiotherapy, 647
Chemo-neutron radiotherapy, 529
Chemosensitization, 301
Chemotherapy, 17, 25, 705, 1089
Chloramphenicol, 307
Chronic hypoxia, 255
Cisplatin, 771, 1027
Clinical trials, 1049
Clonogenic fraction, 57
Cobalt(III) complex, 323
Colon cancer, 277
Combined modality(ies), 481, 1027
  Therapy, 153, 735
Complications, 529, 953
Computed tomography, 863
Concomitant chemoradiotherapy, 153
Conformal radiation therapy, 755
Conservative treatment, 17
Craniospinal irradiation, 187
Cryospectrophotometry, 459
Cultured, 511
Cumulative incidence, 1183
Cyclophosphamide, 39, 387, 545, 847
Cyclosporine, 847
Cytochrome C, 635
Cytochrome P-450, 277

D

Determinants of radiocurability, 57
Differential action, 635
Diffusible cytotoxin(s), 317, 323
Diltiazem, 511
Dimethylxanthenone acetic acid, 373
Dipole antennas, 1065
DNA
  Bases, 307
  Binding, 311
  Polymerase, 133
  Repair, 1035
  Strand breaks, 487
Dose
  Evaluation, 1125
  To air cavity tissue–air interface, 1139
  To larynx, 1139
Dose–volume histogram, 1125
Doxorubicin, 827
Drug
  Release, 827
  Resistance, 387
DT-diaphorase, 231, 295, 351, 369, 427
dUTPase, 519
Dynamic MRI, 473

E

Early and late morbidity, 941
EBI, 673
Effect of microenvironment, 363
Elderly, 835
Electron
  Beam dosimetry, 1157
  Paramagnetic resonance, 421
EMT6 spheroids, 323
Endothelial cells, 249
Endovascular irradiation, 183
Enzyme profiling, 427
EO9, 295
Epidermal growth factor, 243
  Receptor, 813
Epithelial cancer of the eye, 177
Epoxide hydrolase, 277
Eppendorf oxygen electrodes, 439
Erythropoietin (r-HuEPO), 1079
Esophageal cancer, 525
Estramustine, 555
Estrogen receptor, 813
Etanidazole, 87, 289, 407, 535, 541, 545, 571, 611, 617
Etoposide, 39, 621
Eulexin, 755
Experimental tumors, 463
External beam therapy, 1133

F

^{19}F NMR, 95
Fast neutron, 239
FIGO classification, 941
5-fluorouracil, 519
5-iodo-2′-deoxiuridine, 105
Flavone acetic acid, 373
Fluorinated 2-nitroimidazole derivative, 579
Fluorine radioisotope, 841
Fluoroscopy, 863
Foot, 735
4-OOH-CP, 301
Fractionated
  Irradiation, 583, 591
  Radiotherapy, 141, 1147
Free radicals, 421
FSa-II tumor, 141

G

Gamma-glutamylcysteine synthetase, 407
Gastrointestinal, 961
Gd-DTPA, 473
Gene expression, 813
General and radiobiological factors, 673
Genitourinary, 961
Germinoma, 1089
Glioblastoma, 407, 835
  Multiforme, 719
Glioma, 427
Glucose metabolism, 571
Glutathione, 383, 393, 403, 407, 771
Graft failure, 847
Graft-versus-host disease, 847
Gynecologic, 961

H

Halogenated pyrimidines, 105
Hand, 735
Hazard rates, 1183
HDR-brachytherapy, 183
Head and neck
  Cancer(s), 45, 149, 153, 661, 687
  Tumors, 1049
Helical antennas, 1065
Helium ions, 647
Hematoxicity, 115
Hep3B cells, 397
Hepatom, 277
Heterogeneity, 1157
High-LET, 115
Histological types, 975
Histopathology, 73
Hodgkin's disease, 25
Hoechst 33258 DNA strand breaks, 549
HT-29, 363
Human(s), 455
  Umbilical cord blood, 821
  Xenografts, 57
Human brain tumor(s), 427
  Cells, 1041
Human tumor cell(s), 369
  Lines, 1035
Hydralazine, 473, 505
Hydrogen peroxide, 357
Hydroxamic acid, 601
Hyperfractionation, 45
Hyperthermia, 125, 141, 511, 525, 821, 827, 1065
  Techniques, 1049
Hypoxia, 87, 231, 259, 373, 427, 449, 481, 493
  Effect on cytotoxicity, 363
  Of normal tissue, 487
  Of tumor, 487
Hypoxic
  Cytotoxic agents, 379
  Fraction (HF), 583
  Markers, 351
  Selectivity, 311
  Sensitization, 295
Hypoxic cell
  Fraction, 57
  Radiosensitizer(s), 571, 579, 587, 591, 595, 601
  Sensitizer, 541, 545, 583

I

IL-1 normal tissues: endogenous cytokines, 805
Immobilization device, 879
Immunocompetence, 821
Immunofluorescence staining, 239
Immunohistochemistry, 277
Immunomodulators, 627
In phantom measurements, 1175
In vitro effect, 631
In vivo diode dosimetry, 1175
Inflated cuff procedure, 455
Inhomogeneity, 1157
Interleukin 1, 805
Internal mammary nodes, 903
Interstitial
  Brachytherapy, 719
  Hyperthermia, 1049
Intestine, 81, 781
Intimal hyperplasia, 183
Intracavitary gynecologic brachytherapy, 969
Intraoperative radiotherapy, 781, 1015
Intratumoral chemotherapy, 1027
Intrinsic radiosensitivity, 57
Iodinated DNA ligands, 549
Iodine-125, 719
Ionizing radiation, 249, 813

K

Kaplan–Meier, 1183
Karnofsky performance status, 835
K curve, 323
Ketoconazole, 777
KHT sarcoma, 459, 473
KIN-804, 595, 601
KU-2285, 571, 579, 583, 587, 591, 595

L

Lacrimal
  Cancer, 177
  Collecting system, 1095
  Sac, 1095
Laryngeal carcinoma, 657
Larynx, 841
Late
  Complications, 1183
  Effects, 73, 781
Leukemia, 1167
Leuprolide, 755
Limb preservation, 735
Lipoxygenase, 777
Liver, 277
L929 cells, 467
Local
  Control, 153, 1183
  Neoplasm recurrence, 841
  Tumor control, 529
Locally advanced, 873
Long-circulating liposomes, 827
Lonidamine, 45, 999
Low doses, 87
Low-dose rate
  Brachytherapy, 953
  Intracavitary brachytherapy, 975
Lower gingiva, 705
Lung cancer, 635, 1085, 1105
Lymphoid, 1095, 1095
Lysosomal uptake, 311

M

Magnetic resonance imaging (MRI), 473
Malignant glioma, 719
Mammary adenocarcinoma, 141
Marrow transplantation, 39
MDAH-MCa-4 tumor, 373
MDRI, 81
Mechlorethamine, 317
Melanoma, 403
Melphalan, 463, 541
Metallothionein, 397
Mice, 627
Micronucleus assay, 239, 587
Microwave(s), 1049, 1065
Minor groove binding DNA ligands, 549
Misonidazole, 87
Misoprostol, 273
Misrepair, 1035
Mitomycin C, 363
Morphology, 771
Mouse bone marrow cells, 631
MRI, 95, 1095
mRNA, 397
Multiple
  Daily fractions, 961
  Head and neck, 681
  Myeloma, 541
Multivariate analysis, 673
Murine, 459
  Tumors, 439
Muscle
  Blood perfusion, 473
  Cramping, 379
Myelopathy, 763

N

NADH cytochrome b5, 427
NADPH cytochrome P-450 reductase, 427
Nasolacrimal
  Duct, 1095
  Sac cancer, 177
Nasopharyngeal carcinoma, 699
Neoadjuvant hormonal therapy, 755
Neoplasm(s), 841, 855, 1095, 1119
Neoplastic cells, 511
Nervous system, 771
Neurophysiology, 771
Neurosurgery, 711
Neurotoxicity, 535, 571
Neutron brachytherapy, 529
Nicotinamide, 455
Nimorazole, 87
Nine bioreductive agents, 329
Nitric oxide synthase, 443
Nitro-L-arginine, 443
Nitrogen mustard, 323
Nitroimidazole, 601
Nitroquinoline, 311
Nitroreductases, 351
Nitrosochloramphenicol, 307
Nitroxides, 421
Nonelectronic equilibrium, 1139
Nonsmall cell, 1105
  Lung cancer, 33, 999
Normal tissue, 487
  Effects, 781
  Tolerance, 1015
Nuclear antigen, 661
Nude mice, 525

O

OK-432, 631
Oncogenic transformation, 267, 273
1-electron reduction, 333
Operable lung cancer, 33
Oral
  Cancer, 383
  Tongue carcinoma, 673

Oropharynx, 681
Outcome, 1005
Ovarian
  Cancer, 545
  Neoplasms, 169
Overall treatment time, 983
Oxidative stress, 289
Oxygenation, 421
Oxyhemoglobin modifiers, 285

P

Palliation, 961
Palliative irradiation, 1011
Patient
  Dose quality assyrance, 1175
  Movement, 1147
  Positioning, 869, 1147
PD 144872, 301
PDT, 463
Pelvic tumors, 1049
Pentose cycle, 357
Pentoxifyline, 433
Penumbra modifier, 187
Perfluorocarbon, 95
Perioperative morbidity, 969
Peripheral
  Neuropathy, 535
  Neurotoxicity, 591
p50, 449
P450 reductase, 351
pH effect on cytotoxicity, 363
Pharmacokinetic(s), 339, 463, 535, 591, 595
  Parameters, 607
Photodynamic therapy (PDT), 231, 329
Photogrammetry, 1147
Pineoblastoma, 729
Pituitary shield, 699
Plasma GSH, 383
Plasmid, 1035
PLDR, 255
^{31}P magnetic resonance spectroscopy (MRS), 231, 285, 443
pO_2, 95
pO_2 distribution, 427
p105, 661
Positron emission tomography, 841
Postoperative radiation therapy, 989
Potentially lethal damage repair, 239, 577
Predictive assay, 661
Preincubation effect, 345
Prognostic
  Factors, 9, 711
  Parameters, 1049
Proliferation, 661
Prolonged treatment and local control, 657
Prostaglandins, 273
Prostate, 863, 1119
  Apex, 1133
  Cancer, 611, 755, 1133
  Carcinoma, 555
  Tumor, 95
Protein kinase C, 259
Pyrazine mono-*N*-oxides, 339

Q

Quality assurance, 869
Quality of life, 835
Quiescent cell, 239

R

Radiation, 267, 393, 565, 1095
  Enhancement, 999
  Injuries, 841
  Mucositis, 383
  Myelopathy, 67, 73
  Resistance, 1035
  Response, 255, 449
  Sensitizer(s), 105, 379, 535, 555, 611, 617
  Sensitizing agents, 345
  Sequelae, 777
Radiation damage, 73
  Repair, 893
Radiation therapy (RT), 9, 719, 735, 869, 903, 1079
  Treatment course, 657
Radical
  Radiotherapy, 33
  Vulvectomy, 989
Radiobiological hypoxia, 439
Radiography, 1119
Radiolysis, 333
Radiopotentiation, 1041
Radioprotection, 273, 621, 627, 747
Radiosensitization, 243, 481, 549
Radiosensitizers, 87, 519
Radiosensitizing
  Activity, 579
  Effect, 595
Radiotherapy, 17, 25, 45, 169, 699, 705, 835, 855, 873, 941, 983, 1005, 1049, 1089
  Dosage, 169
RB90740, 333
RB 6145, 301
Recruitment, 805
Rectal adenocarcinoma, 115
Recurrence, 719
  Patterns, 989
Reductase, 277
Reduction of tirapazamine, 427
Regrowth delay, 463
Rehypoxiation, 493
Reirradiation, 687
Reoxygenation, 141, 255, 493, 583
Repair, 133
Repopulation, 805
Reproducibility, 1175
Response rates, 1011
Restriction endonucleases, 1035
Retinoblastoma, 393, 729
Retreatment, 1011
Retroperitoneal, 1005
Retroperitoneum, 781
RIF-1 tumor, 329, 827
RK-28, 571
RP-170, 571

S

Salivary glands, 747
SAR, 1065
Sarcoma, 735
SCCVII
  Carcinoma, 459
  Tumor, 81, 449
Scintillation detector, 1157
Second
  Cancers, 25
  Head and neck carcinoma, 681
Seminoma, 3
Sensitizing effect, 607
Signal transduction, 259
Single brain metastasis, 711
Skull base tumors, 647
Smoking, 449
SN 23862, 373
SN 24771, 323
Soft tissue sarcoma, 1005
Spermine analog, 1041
Spheroids, 317
Spinal cord, 67, 73
Spontaneous tumors, 443
Squamous cell
  Cancer, 243
  Carcinoma, 705
SR-2508, 289, 587
SR-4077, 249
SR 4233, 357, 363, 373, 379, 493
Stents, 183
Supra-additive, 267
Synchronized cells, 565

T

Targeted α-endoradiotherapy, 115
Taxol, 267, 565
Temperal optimization, 893
Tert-butyl hydroperoxide, 249
Therapeutic radiology, 1119
Thermochemotherapy, 827
Thermoradiosensitization, 133
Thermoradiotherapy, 125, 141, 505
Thiol(s), 387
  Depletion, 345
3-aminobenzamide, 577
Three-dimensional (3-D) treatment planning, 903, 1105, 1125
Three-year survival, 529
Thymidine labelling index, 805
Thymidylate synthase, 519
Time–dose relationship, 153
Tirapazamine, 369, 379, 493
Tirazamine (WIN 59075, SR 4233), 427
TNF cytotoxicity, 467
Tolerance, 529
Total
  Body irradiation, 39, 1167
  Lymphoid irradiation, 847
Toxicity, 771
Toxicology, 771
TPA, 259
Transcription, 397
Transient hypoxia, 487
Transplantable tumors, 443
Treatment planning, 1119, 1133
Trilateral retinoblastoma, 729
Tumor(s), 487, 571
  Hypoxia, 285
  Microenvironment, 467
  Necrosis factor, 777
  pH, 125
  Response, 125
  Size, 9, 505
Tumor blood
  Flow, 433
  Perfusion, 449, 473
Tumor oxygenation, 459, 467
  Status, 439
Tumoral, general and radiobiological factoars, 673
2-nitorimidazole(s), 345, 351, 535, 611, 617
  Derivative, 579

U

UDP-glucuronyl transferase, 277
Ureter, 781

Urethra, 1119
V79-WNRE, 363

V

Vaginal cancer, 983
Vascular grafts, 1015
Vasoactive, 373
Velotonsillar carcinoma, 681
Vena cava, 781
Verapamil, 511
Verification films, 869
Vitamin E succinate, 289
Volume effects, 67, 763
Vulvar carcinoma, 989

W

Whole-body irradiation, 621
WR-2721, 747

X

X ray, 577
Xenobiotic-metabolising enzymes, 277
Xenografts, 481

Y

Young and mature pigs, 763